IN THE CLAIMS

1. (Currently amended) A fast disintegrating controlled release oral composition comprising a core material containing cefuroxime axetil present as controlled release form, and optionally probenecid, said controlled release form comprising

a) an outer coating of a ~~copolymer~~ polymer selected from aqueous dispersions of enteric methacrylic acid and methacrylic acid esters anionic copolymers having carboxygroup as the functional group or mixtures thereof and;

b)an inner coating of a sustained-release copolymer selected from aqueous dispersions of acrylate and methacrylate pH independent, neutral copolymers having quaternary ammonium group as a functional group or mixtures thereof; said composition releases cefuroxime axetil in amounts of ~~wherein under normal conditions of use~~ more than 80% ~~of the cefuroxime axetil is released~~ in 4 hours and the outer coating controls the initial rapid release of cefuroxime axetil from the composition ~~does not enhance the rate of drug release from the composition~~.

2. (Previously presented) A composition as claimed in claim 1 wherein probenecid is present as controlled release form.

3. (Previously presented) A composition as claimed in claim 1 containing from about 30 % to about 80 % of cefuroxime axetil by weight of controlled release form.

4. (Previously presented) A composition as claimed in claim 1 wherein a multidose contains 500 mg to 2 g cefuroxime.

5. (Previously presented) A composition as claimed in claim 1 containing cefuroxime axetil in an amount which is equivalent to cefuroxime from 250 mg to 1500 mg.

6. (Previously presented) A composition as claimed in claim 1 wherein cefuroxime axetil is essentially amorphous.

7. (Previously presented) A composition as claimed in claim 1 wherein a) and b) are present in an amount from about 1 % to about 30 % by weight comprising from about 0.1 % to about 15 % of each copolymer present in the composition, by weight of controlled release form.

8. (Previously presented) A composition as claimed in claim 1, wherein the outer enteric coating comprises a poly(ethylacrylate, methacrylic acid) with a molar ratio of 1:1 and average molecular weight around 250,000.

9. (Previously presented) A composition as claimed in claim 1, wherein the inner coating comprises a mixture of a first copolymer, poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.2 and a molecular weight of 150,000 and a second copolymer, a poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.1 and a molecular weight of 150,000.

10. (Previously presented) A composition as claimed in claim 1, wherein the ratio of inner coating to outer coating is in the range of 1:0.3 to 1:5.

11. (Previously presented)A composition as claimed in claim 1, wherein the ratio of inner coating to outer coating is in the range of 1:0.5 to 1:4.

12. (Previously presented) A composition as claimed in claim 9, wherein the first copolymer of the inner coating comprises a poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.2 and a molecular weight of 150,000 in the range of about 1 % to about 8 % by weight of controlled release form.

13. (Previously presented) A composition as claimed in claim 9, wherein the second copolymer of the inner coating comprises a poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.1 and a molecular weight of 150,000 in the range of about 0.1 % to about 5 % by weight of controlled release form.

14. (Previously presented) A composition as claimed in claim 9, wherein the inner coating comprises a mixture of a first copolymer, poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.2 and a molecular weight of 150,000 and a second copolymer, a poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.1 and a molecular weight of 150,000; the ratio of said second copolymer-to said first copolymer being in the range of 1:1 to 1:10.

15. (Previously presented) A composition as claimed in claim 9, wherein the inner coating comprises a mixture of a first copolymer, poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.2 and a molecular weight of 150,000 and a second copolymer, a poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.1 and a molecular weight of 150,000; the ratio of said second copolymer to said first copolymer being in the range of 1:1 to 1:8.

16. (Previously presented) A composition as claimed in claim 1 wherein the outer coating comprises from about 2% to about 10 % by weight of controlled release form.

17. (Previously presented) A composition as claimed in claim 1 wherein the outer coating comprises from about 2 to about 8 % by weight of controlled release form.

18. (Previously presented) A composition as claimed in claim 1 wherein the inner coating comprises from about 1 to about 12 % by weight of controlled release form.

19. (Previously presented) A composition as claimed in claim 1 wherein the inner coating comprises from about 1 to about 9 % by weight of controlled release form.

20. (Previously presented) A composition as claimed in claim 1, wherein the total dry polymeric content is about 5 to about 30 % by weight of the controlled release form.

21.(Previously presented) A composition as claimed in claim 1, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1% to about 25% by weight of a mixture of a) and b) wherein the inner polymeric coat comprises from about 1% to about 12% by weight and the outer polymeric coat comprises from about 2% to about 10% by weight of controlled release form.

22. (Previously presented) A composition as claimed m claim 1, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1 % to about 20% by weight of a mixture of a) and b) wherein the inner polymeric coat comprises from about 1 % to about 9% by weight and the outer polymeric coat comprises from about 2% to about 8% by weight of controlled release form.

23. (Previously presented) A composition as claimed in claim 1 containing probenecid in an amount from 250 mg to 1000 mg.

24. (Previously presented) A composition as claimed in claim 1, which further contains at least one water soluble or water dispersible diluent.

25. (Previously presented) A composition as claimed in claim 24, wherein the water soluble or water dispersible diluent comprises about 1 % to about 25 % by weight of the composition.

26. (Previously presented) A composition as claimed in claim 24, wherein the water dispersible diluent comprises about 5 % to about 25 % by weight of the controlled release form.

27. (Previously presented) A composition as claimed in claim 26, wherein the water dispersible diluent is microcrystalline cellulose.

28. (Previously presented) A composition as claimed in claim 1, which further contains a wetting agent in amount from about 0.1 % to about 4 % by weight of controlled release form.

29. (Previously presented) A composition as claimed in claim 28 wherein the wetting agent is sodium lauryl sulphate.

30. (Previously presented) A composition as claimed in claim 1, which further contains a lubricant in an amount from about 0.1 % to about 5 % of the composition.

31. (Previously presented) A composition as claimed in claim 30 wherein the lubricant is hydrogenated vegetable oil.

32. (Previously presented) A composition as claimed in claim 1, which further contains a disintegrant in amount from about 1 % to about 25 % by weight of the composition.

33. (Previously presented) A composition as claimed in claim 32, wherein the disintegrant is cross linked carboxymethyl cellulose sodium.

34. (Previously presented) A composition as claimed in claim 1, which further contains a binder in amount from about 1 % to about 5 % by weight of the composition.

35. (Previously presented) A composition as claimed in claim 34, wherein the binder is polyvinyl pyrrolidone.

36. (Previously presented) A composition as claimed in claim 1, wherein the inner coating contains a plasticizer.

37. (Previously presented) A composition as claimed in claim 1, wherein the outer coating contains a plasticizer.

38. (Previously presented) A composition as claimed in claim 36, wherein the plasticizer is present in an amount of from about 1 % to about 20 % by weight of dry polymer.

39. (Previously presented) A composition as claimed in claim 38, wherein the plasticizer is triethyl citrate.

40. (Currently amended) A process for preparing a fast disintegrating controlled release oral composition containing cefuroxime axetil as controlled release form and optionally probenicid as claimed in claim 1, which comprises spraying onto a fluidized bed of cefuroxime axetil core material an aqueous dispersion of an inner polymeric coating, retrieving and drying the coated core material and applying to a fluidized bed of the dried material an aqueous dispersion of an outer polymeric coating material and drying the coated particles wherein the inner polymeric coating is a mixture of a first copolymer, poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.2 and a molecular weight of 150,000 and a second copolymer, a poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.1 and a molecular weight of 150,000; and the outer polymeric coating is a poly(ethylacrylate, methacrylic acid) with a molar ratio of 1:1 and average molecular weight around 250,000, wherein the first copolymer of inner coating is present in amount of about 1 to about 8 %, the second copolymer of inner coating is present in amount of about 0.1 to about 5 % and outer coating is present in amount of about 2 % to about 10 % by weight of controlled release form, respectively.

41. (Previously presented) The process according to claim 40 wherein the inner polymeric coating optionally contains a plasticizer, and further wherein the outer polymeric coating optionally contains a plasticizer.

42. (Previously presented) A process for the preparation of a pharmaceutical composition as claimed in claim 1comprising mixing together cefuroxime axetil, diluents and wetting agent to form a blend, further compacting or wet granulating,

sizing and coating the granules by wet granulation or coating in fluidized bed processor using copolymers a) and b), further drying, sizing, lubricating the granules and compressing to form monolithic tablets or bilayered tablets.

43. (Previously presented) A process for the preparation of a pharmaceutical composition as claimed in claim 1 comprising mixing together cefuroxime axetil, diluents and wetting agent to form a blend, further compacting or wet granulating, sizing and coating the granules by wet granulation or coating in fluidized bed processor using copolymers a) and b), further drying, sizing, lubricating the granules and compressing into tablets along with immediate release probenecid granules to form monolithic tablets or bilayered tablets.

44. (Previously presented) A process for the preparation of pharmaceutical composition as claimed in claim 1 comprising mixing together probenecid, diluent and disintegrant together, compacting or wet granulating, sizing and coating the granules by wet granulation or coating in fluidized bed processor using copolymers a) and b), further drying, sizing, lubricating the granules and compressing into tablets along with coated controlled release cefuroxime axetil granules to form monolithic tablets or bilayered tablets.

45. (Previously presented) A process for the preparation of pharmaceutical composition as claimed in claim 1 comprising mixing together probenecid, diluent and disintegrant together, compacting or wet granulating, sizing and blending with lubricant and compressing the blend into tablets along with controlled release coated granules of cefuroxime axetil to form monolithic tablets or bilayered tablets.

46. (Previously presented) A process for the preparation of a pharmaceutical composition as claimed in claim 40wherein the inlet and outlet air temperatures of fluid bedprocessor are maintained between 40° C to 65° C and 20° C to 40° C, respectively.

47. (Previously presented) A process for the preparation of a pharmaceutical composition as claimed in claim 40 wherein the inlet and outlet air temperatures of

fluid bed processor are maintained between 55° C to 65° C and 30° C to 40° C, respectively.

48. (Currently amended) A composition as claimed in claim 8, wherein the ratio of inner coating to outer coating is in the range of ~~1:0.3 to I:5~~ 1:0.3 to 1:5 .

49. (Previously presented) A composition as claimed in claim 9, wherein the ratio of inner coating to outer coating is in the range of 1:0.3 to 1:5.

50. (Previously presented) A composition as claimed in claim 8, wherein the ratio of inner coating to outer coating is in the range of 1:0.5 to 1:4.

51. (Previously presented) A composition as claimed in claim 9, wherein the ratio of inner coating to outer coating is in the range of 1:O.5 to 1:4.

52. (Previously presented) A composition as claimed in claim 8, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1% to about 25% by weight of a mixture of a) and b) wherein the inner polymeric coat comprises from about 1 % to about 12% by weight and the outer polymeric coat comprises from about 2% to about 10% by weight of controlled release form.

53. (Previously presented)A composition as claimed in claim 9, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1% to about 25% by weight of a mixture of a) and b) wherein the inner polymeric coat comprises from about 1% to about 12% by weight and the outer polymeric coat comprises from about 2% to about 10% by weight of controlled release form.

54. (Previously presented) composition as claimed in claim 8, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1 % to about 20% by weight of a mixture of a) and b) wherein the inner polymeric coat comprises from about 1% to about 9% by weight and the outer

polymeric coat comprises from about 2% to about 8% by weight of controlled release form.

55. (Previously presented) A composition as claimed in claim 9, wherein the controlled release form comprises from about 30% to about 80% by weight of cefuroxime axetil and about 1% to about 20°/o by weight of a mixture of a) and b) wherein the inner polymeric coat comprises from about 1% to about 9% by weight and the outer polymeric coat comprises from about 2% to about 8% by weight of controlled release form.

56. (Previously presented) A composition as claimed in claim 37, wherein the piasticizer is present in an amount of from about 1% to about 20% by weight of dry polymer.

57. (Previously presented) A composition as claimed in claim 56, wherein the plasticizer is triethyl citrate.

58. (Previously presented)A process for the preparation of a pharmaceutical composition as claimed in claim 42, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 40° C to 65° C and 20° C to 40° C, respectively.

59. (Previously presented) A process for the preparation of a pharmaceutical composition as claimed in claim 43, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 40° C to 65° C and 20° C to 40° C, respectively.

60. (Previously presented)A process for the preparation of a pharmaceutical composition as claimed in claim 44, wherein tile inlet and outlet air temperatures of fluid bed processor are maintained between 40° C to 65° C and 20° C to 40° C, respectively.

61. (Previously presented) A process for the preparation of a pharmaceutical composition as claimed in claim 42, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 55° C to 65° C and 30° C to 40° C. respectively.

62. (Previously presented) A process for the preparation of a pharmaceutical composition as claimed in claim 43, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 55° C to 65° C and 30° C to 40° C. respectively.

63. (Currently amended) A process for the preparation of a pharmaceutical composition as claimed in claim 44 ~~clairn 4~~, wherein the inlet and outlet air temperatures of fluid bed processor are maintained between 55° C to 65° C and 30° C to 40°.C respectively.

64. (New) A fast disintegrating controlled release oral composition comprising a core material containing cefuroxime axetil present as controlled release form, and probenecid, said controlled release form comprising

a) an outer coating of a polymer selected from aqueous dispersions of enteric methacrylic acid and methacrylic acid esters anionic copolymers having carboxygroup as the functional group or mixtures thereof and;

b)an inner coating of a sustained-release copolymer selected from aqueous dispersions of acrylate and methacrylate pH independent, neutral copolymers having quaternary ammonium group as a functional group or mixtures thereof; said composition releases cefuroxime axetil in amounts of more than 80% in 4 hours and the outer coating controls the initial rapid release ofcefuroxime axetil from the composition.

65. (New) A process for preparing a fast disintegrating controlled release oral composition containing cefuroxime axetil as controlled release form and probenicid as claimed in claim 1, which comprises spraying onto a fluidized bed of cefuroxime

axetil core material an aqueous dispersion of an inner polymeric coating, retrieving and drying the coated core material and applying to a fluidized bed of the dried material an aqueous dispersion of an outer polymeric coating material and drying the coated particles wherein the inner polymeric coating is a mixture of a first copolymer, poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.2 and a molecular weight of 150,000 and a second copolymer, a poly(ethylacrylate, methylmethacrylate, trimethylammonioethyl methacrylate chloride) with a molar ratio of 1:2:0.1 and a molecular weight of 150,000; and the outer polymeric coating is a poly(ethylacrylate, methacrylic acid) with a molar ratio of 1:1 and average molecular weight around 250,000, wherein the first copolymer of inner coating is present in amount of about 1 to about 8 %, the second copolymer of inner coating is present in amount of about 0.1 to about 5 % and outer coating is present in amount of about 2 % to about 10 % by weight of controlled release form, respectively.